Drug Profile
BMS 188184
Latest Information Update: 18 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Anti-inflammatories; Antipsoriatics
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atopic dermatitis; Psoriasis
Most Recent Events
- 18 Jan 2005 Discontinued - Phase-I for Atopic dermatitis in USA (Topical)
- 18 Jan 2005 Discontinued - Phase-I for Psoriasis in USA (Topical)
- 02 Mar 2000 No-Development-Reported for Atopic dermatitis in USA (Topical)